3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Glioma
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Hyperplasia
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Calcinosis
1
Breast Neoplasms
1
Brain Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled